

Electronic Acknowledgement Receipt

EFS ID:	7549258
Application Number:	10664803
International Application Number:	
Confirmation Number:	3478
Title of Invention:	NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE
First Named Inventor/Applicant Name:	Unchalee Kositprapa
Customer Number:	47888
Filer:	Nicholas P. Chiara
Filer Authorized By:	
Attorney Docket Number:	141-424
Receipt Date:	04-MAY-2010
Filing Date:	19-SEP-2003
Time Stamp:	16:49:47
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$990
RAM confirmation Number	3419
Deposit Account	505222
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	141424RCE.pdf	797972	no	3
			a2df823716c989b47171014c6cb93a58bb52c750		
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed (SB/08)	141424SB08a.pdf	40914	no	4
			e78f946cc966d874965741c9fe4ecb64cedcf534		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Transmittal Letter	141424SupplDStrans.pdf	87617	no	2
			5b87b48970ba400c49fadca9c81be8dffbd0da312		
Warnings:					
Information:					
4	NPL Documents	NPL1.pdf	2670505	no	10
			e18ac8401db0a7659b75aacb948fc073b630ec7d		
Warnings:					
Information:					
5	NPL Documents	NPL2.pdf	47367	no	1
			22261e85d77a545a28e398ea800269f94549dad2		
Warnings:					
Information:					
6	NPL Documents	NPL3.pdf	2680947	no	10
			5384d48bcfeca9a2b99372819019e821083660dc		
Warnings:					
Information:					
7	NPL Documents	NPL4.pdf	1975035	no	12
			818038a12482570034981a0ace2649281ef065d9		
Warnings:					
Information:					
8	NPL Documents	NPL5.pdf	2983479	no	12
			3e9cca93c9da884ba4b41ee192fcdad2f7d8dd9f5		
Warnings:					
Information:					

9	NPL Documents	NPL6.pdf	5860815 eaf0ee73a1a3a363360119a7d50972f23ca0d6e	no	29
Warnings:					
Information:					
10	Fee Worksheet (PTO-875)	fee-info.pdf	32148 bdf6257f758a0206cc580d6ccbff64fcaeea931	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			17176799		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					